- Previous Close
39.84 - Open
39.67 - Bid 39.64 x 100
- Ask 40.13 x 100
- Day's Range
38.50 - 41.35 - 52 Week Range
36.52 - 58.26 - Volume
431,032 - Avg. Volume
436,098 - Market Cap (intraday)
2.522B - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-1.89 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
77.77
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
www.moonlaketx.comRecent News: MLTX
View MorePerformance Overview: MLTX
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MLTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MLTX
View MoreValuation Measures
Market Cap
2.52B
Enterprise Value
2.08B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.81%
Return on Equity (ttm)
-25.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-118.94M
Diluted EPS (ttm)
-1.89
Balance Sheet and Cash Flow
Total Cash (mrq)
448.03M
Total Debt/Equity (mrq)
0.62%
Levered Free Cash Flow (ttm)
-92.06M